NO20092597L - Renininhibitorer for prevensjon og behandling av hypertensjon hos overvektige pasienter - Google Patents

Renininhibitorer for prevensjon og behandling av hypertensjon hos overvektige pasienter

Info

Publication number
NO20092597L
NO20092597L NO20092597A NO20092597A NO20092597L NO 20092597 L NO20092597 L NO 20092597L NO 20092597 A NO20092597 A NO 20092597A NO 20092597 A NO20092597 A NO 20092597A NO 20092597 L NO20092597 L NO 20092597L
Authority
NO
Norway
Prior art keywords
obese patients
hypertension
prevention
treatment
renin inhibitors
Prior art date
Application number
NO20092597A
Other languages
English (en)
Inventor
Margaret Forney
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39186152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20092597(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20092597L publication Critical patent/NO20092597L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører fremgangsmåter til forebyggelse av, forsinke utvikling av eller behandling av hypertensjon hos fedmepasienter innbefattende inntak til et varmblodig dyr av en terapeutisk effektiv mengde av en renininhibitor, slik som aliskiren eller et farmasøytisk akseptabelt salt. Renininhibitoren kan anvendes alene eller i kombinasjon med et annet antihypertensjonsmiddel, i særdeleshet et urindrivende middel, slik som hydroklortiazid.
NO20092597A 2006-12-15 2009-07-08 Renininhibitorer for prevensjon og behandling av hypertensjon hos overvektige pasienter NO20092597L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87018006P 2006-12-15 2006-12-15
PCT/US2007/087322 WO2008074001A1 (en) 2006-12-15 2007-12-13 Renin inhibitors for the prevention and treatment of hypertension in obese patients

Publications (1)

Publication Number Publication Date
NO20092597L true NO20092597L (no) 2009-07-13

Family

ID=39186152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092597A NO20092597L (no) 2006-12-15 2009-07-08 Renininhibitorer for prevensjon og behandling av hypertensjon hos overvektige pasienter

Country Status (18)

Country Link
US (1) US20100029775A1 (no)
EP (1) EP2094259A1 (no)
JP (1) JP2010513300A (no)
KR (1) KR20090090384A (no)
CN (1) CN101583355A (no)
AU (1) AU2007333095B2 (no)
BR (1) BRPI0721167A2 (no)
CA (1) CA2672579A1 (no)
CL (1) CL2007003628A1 (no)
IL (1) IL198876A0 (no)
MA (1) MA31003B1 (no)
MX (1) MX2009006340A (no)
NO (1) NO20092597L (no)
RU (1) RU2009126741A (no)
TN (1) TN2009000240A1 (no)
TW (1) TW200831071A (no)
WO (1) WO2008074001A1 (no)
ZA (1) ZA200903442B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders
WO2007047351A2 (en) * 2005-10-13 2007-04-26 Orexigen Therapeutics, Inc. Methods for treating hypertension in overweight and obese individuals
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method

Also Published As

Publication number Publication date
BRPI0721167A2 (pt) 2014-03-18
TW200831071A (en) 2008-08-01
US20100029775A1 (en) 2010-02-04
RU2009126741A (ru) 2011-01-20
MX2009006340A (es) 2009-06-23
ZA200903442B (en) 2010-05-26
AU2007333095B2 (en) 2011-03-24
WO2008074001A8 (en) 2009-07-02
IL198876A0 (en) 2010-02-17
CL2007003628A1 (es) 2008-07-18
AU2007333095A1 (en) 2008-06-19
KR20090090384A (ko) 2009-08-25
CA2672579A1 (en) 2008-06-19
EP2094259A1 (en) 2009-09-02
JP2010513300A (ja) 2010-04-30
TN2009000240A1 (en) 2010-10-18
MA31003B1 (fr) 2009-12-01
CN101583355A (zh) 2009-11-18
WO2008074001A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20084256L (no) DPP IV inhibitorformuleringer
WO2010074588A3 (en) Pharmaceutical compounds
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
WO2010039538A3 (en) Flavivirus inhibitors and methods for their use
WO2005023179A3 (en) Combination methods of treating cancer
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
EP1480634A4 (en) TREATMENT OF BENIGN PROSTATIC HYPERPLASIA USING ANDROGEN RECEPTOR (MRSA) SELECTIVE MODULATORS
WO2005049084A3 (en) Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure
CL2008001782A1 (es) Uso de una composicion que comprende un compuesto derivado de heterociclo para tratar o prevenir la perdida de flujo intestinal; composicion que comprende dicho compusto; y kit que comprende la composicion.
AU2008267058A8 (en) Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
NO20090322L (no) 6-(heterosykel-substituert benzyl)-4-oksoquinolin forbindelse samt anvendelse av det samme som IIIV integrave inhibitor
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2007117559A3 (en) Renin inhibitors
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
NO20053455L (no) Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer
NO20092597L (no) Renininhibitorer for prevensjon og behandling av hypertensjon hos overvektige pasienter
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz
WO2009047505A3 (en) Dexanabinol with inhibitors of braf or mek for the treatment of melanoma
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
NO20084625L (no) Renininhibitorer for behandlingen av hypertensjon
WO2006053014A3 (en) Selective inhibition of rock1 in cardiac therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application